Compound comparison
Retatrutide vs Semaglutide
Both are incretin-class peptides studied as reference materials in metabolic research. The difference is scope: semaglutide targets a single receptor (GLP-1), while retatrutide is a triple agonist that adds the GIP and glucagon receptors. Supplied for laboratory research use only; not for human or veterinary use.
| Retatrutide | Semaglutide | |
|---|---|---|
| Compound class | Triple receptor agonist | GLP-1 receptor agonist (mono) |
| Receptor targets | GLP-1 · GIP · glucagon (GCGR) | GLP-1 |
| Molecular formula | C221H342N46O68 | C187H291N45O59 |
| Molecular weight | ≈ 4731.33 Da | ≈ 4113.58 Da |
| CAS number | 2381089-83-2 | 910463-68-2 |
| Developer | Eli Lilly | Novo Nordisk |
| Primary research area | Multi-receptor metabolic research | Incretin / metabolic research |
| Format at TagPep | 60 mg lyophilized research vial | Reference only — not stocked |
Molecular data verified against PubChem and published literature. Molecular weights are average values.
Semaglutide engages the GLP-1 receptor only. Retatrutide engages GLP-1, GIP and glucagon (GCGR) — two additional pathways, which is why it is described as a triple agonist. The added GIP and glucagon receptor activity is the primary axis researchers compare against semaglutide's single-receptor profile.
Each is an investigational synthetic peptide used as a characterized reference material in metabolic and receptor-signaling research, with identity and reported purity confirmed by batch documentation. For the broader class see the multi-receptor agonist primer and the research-peptide reference table.
Retatrutide 60 mg — in stock
Triple GLP-1/GIP/glucagon · lyophilized research vial with batch documentation
Semaglutide is listed for reference only. Browse the full catalog of stocked research compounds in the shop.
Common questions
What is the difference between retatrutide and semaglutide?
Receptor coverage. Semaglutide is a single (mono) agonist acting on the GLP-1 receptor only. Retatrutide is a triple agonist that engages GLP-1, GIP and the glucagon (GCGR) receptors — two additional pathways. Both are synthetic incretin-class peptides studied in metabolic research and supplied for laboratory research use only.
How many receptors does each compound target?
Semaglutide targets one receptor (GLP-1). Retatrutide targets three (GLP-1, GIP and glucagon). Tirzepatide sits between them as a dual GIP/GLP-1 agonist.
Can I buy retatrutide for research?
Yes. TagPep stocks retatrutide as a 60 mg lyophilized research vial with batch-specific analytical documentation, for laboratory research use only. Semaglutide is shown here for reference and comparison.
Related comparisons
This comparison is factual reference information for laboratory research and educational use. Both compounds are research materials supplied for laboratory research use only — not for human or veterinary use, consumption, injection, administration, diagnosis, or treatment. No dosing or administration guidance is provided or implied.